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A B S T R A C T   
Mitochondrial malate dehydrogenase (MDH2) deficiency (MDH2D) is an ultra-rare disease with only three pa-
tients described in literature to date. MDH2D leads to an interruption of the tricarboxylic acid (TCA) cycle and 
malate-aspartate shuttle (MAS) and results in severe early onset encephalopathy. Affected infants suffer from 
psychomotor delay, muscular hypotonia and frequent seizures. Laboratory findings are unspecific, including 
elevated lactate in blood and cerebrospinal fluid. Brain magnetic resonance imaging reveals delayed myelination 
and brain atrophy. Currently there is no curative therapy to treat this devastating disease. 
Here, we present a female patient diagnosed with MDH2D after a stroke-like episode at 18 months. Trio-whole 
exome sequencing revealed compound heterozygous missense variants in the MDH2 gene: c.398C>T, p. 
(Pro133Leu) and c.445delinsACA, p.(Pro149Hisfs*22). MDH2 activity assay and oxygraphic analysis in patient’s 
fibroblasts confirmed the variants were pathogenic. At the age of 36 months, a drug trial with triheptanoin was 
initiated and well tolerated. The patient’s neurologic and biochemical phenotype improved and she had no 
further metabolic decompensations during the treatment period suggesting a beneficial effect of triheptanoin on 
MDH2D. 
Further preclinical and clinical studies are required to evaluate triheptanoin treatment for MDH2D and other 
TCA cycle and MAS defects.   
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1. Introduction 
Ultra-rare genetic defects causing enzyme and transporter de-
ficiencies of the tricarboxylic acid (TCA) cycle and the malate-aspartate 
shuttle (MAS) are devastating diseases associated with an energy un-
dersupply of organs with a high-energy demand such as brain and 
muscle (1,2). Mitochondrial malate dehydrogenase (MDH2; EC 1.1.1.37; 
OMIM *154100) deficiency (MDH2D; OMIM # 617339) is caused by 
mutations in the MDH2 gene and has been described in only three pa-
tients thus far (1). The enzyme is part of the TCA cycle and the MAS 
(3–5) and it catalyses the reversible oxidation of malate to oxaloacetate 
using the NAD+/NADH cofactor system (6). 
Here we describe a four year-old girl suffering from MDH2D. To date 
there is no treatment for MDH2D. Patients suffered from severe early- 
onset epileptic encephalopathy and were treated with anticonvulsant 
drugs and ketogenic diet to reduce seizure frequency (1). 
Our main aim is to bring forward a potential new treatment strategy 
for MDH2D by using triheptanoin in this young patient. Triheptanoin is 
a medium-chain triglyceride (MCT) – the product of esterification of 
glycerol with three molecules of heptanoate (C7). Glycerol is either 
metabolized via glycolysis or it is shuttled into gluconeogenesis. C7 is 
degraded in the β-oxidation giving rise to acetyl-CoA and/or propionyl- 
CoA which replenish the TCA cycle. Alternatively, C7 is utilized for the 
production of ketone bodies (7–9). Triheptanoin has been used in 
various metabolic disorders and refractory epilepsy (9–11) and has 
recently been approved in the USA for the treatment of patients with 
long-chain fatty acid oxidation disorders LC-FAOD (12). In a patient 
cohort with LC-FAOD, triheptanoin significantly reduced hospitalization 
days/year and the hospitalization rate (13). 
The mode of action of triheptanoin is not yet fully understood. 
Acetyl-CoA and propionyl-CoA generated by triheptanoin help maintain 
an appropriate substrate balance for the TCA cycle, supplying peripheral 
tissues with an alternative fuel and improving energy generation for 
gluconeogenesis (9). 
Here, triheptanoin treatment was given as an individual clinical trial 
for a young girl suffering from MDH2D. It was well tolerated during the 
12 months observation period so that the therapy was continued beyond 
the clinical trial for more than two years now. Under triheptanoin 
therapy the patient’s overall health, neurologic development and 
several biochemical parameters improved. Triheptanoin prevented 
metabolic decompensations. Further studies including more MDH2D 
patients are required to evaluate efficiency of this promising treatment 
approach. 
2. Material and methods 
2.1. Patient work-up 
2.1.1. Brain magnetic resonance imaging 
Our patient underwent three brain magnetic resonance (MR) imag-
ing (MRI) examinations at the age of 19, 20 and 24 months, respectively, 
performed in a 1.5-Tesla magnetic resonance unit (Siemens Magnetom 
Aera or Siemens Magnetom Avanto, Siemens, Erlangen, Germany). 
Sequence acquisitions included diffusion-weighted imaging; time-of- 
flight MR angiography; contrast-enhanced MR-angiography; 3D 
sagittal T1-weighted images; axial T2-weighted images; susceptibility- 
weighted imaging; coronal FLAIR sequences and proton MR 
spectroscopy. 
2.1.2. Molecular genetic analysis 
Blood samples from parents and index patient were obtained for DNA 
extraction using chemagic Prepito (PerkinElmer, Waltham, MA, USA). 
Exome sequencing using Agilent SureSelect Human All Exon v6 was 
performed on an Illumina Hiseq 4000 instrument. Reads were mapped 
to human reference genome (hg19) and variants were identified using 
CLC Biomedical Genomics Workbench v5 (Qiagen, Hildesheim, 
Germany). MDH2-variants were confirmed using bi-directional Sanger 
sequencing. 
2.2. Mitochondrial malate dehydrogenase activity assay 
To determine MDH2 activity mitochondria were isolated from fi-
broblasts of four controls and the patient and lysed by sonification as 
described previously (14). Isolation of mitochondrial fraction was vali-
dated in our accredited routine laboratory. Contamination of the mito-
chondrial fraction with cytosolic and peroxisomal proteins was excluded 
by Western Blots revealing absence of a cytosolic p70 S6 Kinase and 
peroxisomal PEX19. MDH2 activity was determined by measuring the 
linear decrease in absorbance at 340 nm at 30 ◦C resulting from the 
oxidation of NADH. One unit oxidizes one μmol of NADH per minute at 
pH 7.4 under the specified conditions (8 mM K2PO4, 0.2 mM NADH, 2 
mM oxaloacetate and 10 μg mitochondrial protein in a total volume of 1 
mL in cuvettes). 
2.3. Galactose stress test and respiratory chain enzyme analysis 
Patient’s dermal fibroblasts were grown from a skin punch biopsy 
and cultured in either standard glucose or galactose containing medium 
(“oxidative” stress test) as described previously (15). Oxidative phos-
phorylation (OXPHOS) was assessed by analyses of the respiratory chain 
(RC) complexes I (NADH-coenzyme Q oxidoreductase), II (succinate-Q 
oxidoreductase), III (Q-cytochromec oxidoreductase), IV (cytochrome c 
oxidase) and V (ATP synthase) in patient’s fibroblast homogenates as 
described previously (15). The activities of complexes were related to 
citrate synthase (CS). Oxygraphic analysis of patient fibroblasts were 
assessed by OROBOROS as described previously (15). 
2.4. Triheptanoin trial 
Triheptanoin oil (Ultragenyx pharmaceutical Inc., CA, USA) was 
administered orally by nasogastric and/or percutaneous endoscopic 
gastrostomy (PEG) tube. The treatment scheme was based on previous 
studies with triheptanoin (13). The initial therapy was designated for 12 
months after which its effects were assessed. Triheptanoin was 
continued thereafter and has now been administered for more than 24 
months. 
Daily caloric requirements are approximately 90 cal per kilogram 
(kg) bodyweight (bw). Recommended target dose of triheptanoin 
equates 30–35% of total daily caloric intake divided into three to five 
portions resulting in a final dose of 55 mL. Triheptanoin was gradually 
introduced over a period of one month. During the 12 months treatment 
period regular and frequent clinical and laboratory parameters were 
assessed. Small amounts of regular child food under strict avoidance of 
rapidly absorbable carbohydrates were taken up by the patient. The rest 
of the required daily calories was administered over the tube in form of 
Nutrini Energy Multi Fiber which is a nutritionally complete tube feed. 
3. Results 
3.1. Case report 
Our patient is the second, female child of healthy, non- 
consanguineous Caucasian parents. Pregnancy, birth and the neonatal 
period were unremarkable. In the first months of life, she suffered from 
several febrile seizures in the context of common viral infections. During 
the first year of life she failed to thrive (Supplementary Fig. 1) and her 
head circumference dramatically dropped from the 97th percentile at 4 
months to the 10th-25th percentile at 19 months of age (Supplementary 
Fig. 1). She developed psychomotor delay and muscular hypotonia. 
At the age of 18 months, she was hospitalized and presented with 
acute signs of a stroke including a dyskinetic and choreatic movement 
disorder predominantly affecting her right extremities. Her speech was 
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slurred and she fell to the right side while sitting and crawling. Plasma 
amino acid and acylcarnitine profiles were normal. Urinary organic 
acids were unremarkable. In contrast, blood and cerebrospinal fluid 
(CSF) lactate levels were elevated to 3.0 mmol/L and 2.25 mmol/L 
(reference <1.7), respectively. The brain MRI scan revealed a subacute 
stroke in the left nucleus lentiformis highly suspicious of a metabolic 
origin (Fig. 1A). On follow-up, there were neither signs of ischemia, 
vasculitis nor haemorrhage (Fig. 1B and C). Strikingly, myelination was 
delayed and there was a symmetric atrophy of the frontal lobes 
(Fig. 1D). Atrophy was of subcortical nature with a slight enlargement of 
the frontal horns of the lateral ventricles with adjacent germinolytic 
cysts (pseudocysts) (Fig. 1E). In addition, there was atrophy of the cul-
men of the cerebellum (Fig. 1F and G). Proton MR spectroscopy revealed 
accumulation of lactate in CSF and the brain parenchyma (Fig. 1H) – 
overall findings highly suspicious of being of metabolic origin. 
Taken together, despite the unspecific nature of our clinical, labo-
ratory and radiographic findings, they were evocative of a metabolic 
disorder. A genetic analysis with trio-whole exome sequencing (trio- 
WES) revealed compound heterozygous missense variants in the MDH2 
gene: c.398C>T, p.(Pro133Leu) inherited from her mother and 
c.445delinsACA, p.(Pro149Hisfs*22) inherited from her father. Ac-
cording to the ACMG guidelines (16) both variants were classified 
pathogenic. While the maternally inherited variant has been described 
previously in all three published cases (1), the c.445delinsACA variant 
has not been described before (Supplementary Table 1). 
The first months following the stroke she developed epileptic sei-
zures (both generalized and absence type). She suffered from several 
episodes of metabolic decompensations in the context of febrile in-
fections, which responded well to anti-catabolic therapy. Prior to initi-
ating the clinical trial with triheptanoin she received antiepileptic 
treatment with lamotrigine and levetiracetam. 
3.2. Mitochondrial malate dehydrogenase activity assay 
Enzymatic MDH2 activity in patient fibroblasts was 37 ± 9.7 mU/mg 
protein (range: 18–56 mU/mg protein) and thus significantly decreased 
compared to control fibroblasts showing an activity of 160 ± 43 mU/mg 
protein (range: 107–211 mU/mg protein, n = 4) confirming MDH2D. 
3.3. Galactose stress test and respiratory chain enzyme analysis 
MDH2D interrupts the TCA cycle and leads to a decreased production 
of reducing equivalents for oxidative ATP production. However, patient 
fibroblasts survived cell culture in a galactose-containing medium 
indicating a normal function of the RC (15,17). In line with this, all 
OXPHOS activities were normal (Table 1). All oxygraphic analysis were 
normal except for a decreased ratio of pyruvate/succinate respiration 
(Table 2). 
Fig. 1. Magnetic resonance imaging (MRI) features. (A) Axial diffusion-weighted imaging (DWI) shows restricted diffusion within the left globus pallidus. (B) Follow- 
up imaging 3 months post stroke shows normalization of DWI and complete resolution with no residual changes on T2-weighed imaging (T2WI, (C)). (D) Axial T2WI 
at the age of 2 years shows slightly delayed myelination in the centrum semiovale, not only posteriorly and superiorly to the occipital horns but also extending 
anteriorly around the bodies of the lateral ventricles. Axial T1WI (E) shows enlargement of the frontal horns and adjacent germinolytic cysts. Coronal FLAIR (F) and 
sagittal T1W images (G) show selective atrophy of the superior vermis (culmen). (H) Long-TE MR spectroscopy chemical shift imaging demonstrates a lactate peak at 
1.33 ppm within the cerebrospinal fluid. 
Table 1 
OXPHOS activities in the patient’s fibroblasts. Normal findings.  
Oxidoreductases Patient(mU/mU 
CS) 
Reference values (mU/ 
mU CS) 
Complex I 0.55 0.27–0.66 
Complex II 0.39 0.34–0.69 
Complex III 0.75 0.68–1.49 
Complex IV 0.89 0.52–1.32 
Complex V 0.22 0.21–0.62 
Citrate synthase (CS) (mU/mg 
protein) 
150.00 92–247  
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3.4. Triheptanoin trial 
3.4.1. Safety of triheptanoin 
Triheptanoin was well tolerated by our patient. Except for frequent 
hiccups no adverse events were reported. During the entire treatment 
period she did not suffer from any metabolic decompensation. Prior to 
receiving triheptanoin she suffered from several metabolic de-
compensations leading to six emergency consultations and/or hospi-
talisations. During the fifth month of the trial, she was hospitalized only 
once to install a PEG tube. 
3.4.2. Clinical efficacy of triheptanoin 
Under treatment with triheptanoin, the patient’s weight normalized, 
while microcephaly persisted (Supplementary Fig. 1). According to the 
“Manual Ability Classification System (MACS)” and the „Gross Motor 
Functions Classification System (GMFCS)“ her manual skills and gross 
motor functions remained constant over time and slightly improved, 
respectively (data not shown) (18). To receive a more detailed view on 
changes of her choreatic and hyperkinetic movement disorders during 
the treatment period with triheptanoin, video ratings were performed 
and analysed (Fig. 2 and Supplementary Table 2). Her movements (e.g., 
reaching, grasping, use of both arms) got more purposeful over time. 
During treatment, trunk control as well as her ability to sit and stand 
improved. Furthermore, progress in verbal skills and functional play was 
observed. “Clinical Global Impression (CGI)” assessments revealed an 
improvement over time. Taken together several objective criteria 
revealed a beneficial effect of triheptanoin on the patient’s clinical, i.e. 
neurologic condition. These findings were further substantiated by the 
parents’ observations. The girl’s progress could be supported with the 
aid of lower leg orthosis, Norsk Funktion-walker orthosis and a special 
wheel chair. According to the parents, the patient steadily improved her 
behaviour during the treatment period. They reported an increased 
attention span and more interactions with her environment. 
3.4.3. Biochemical effects of triheptanoin 
Before and upon triheptanoin treatment, repeated laboratory in-
vestigations revealed several normal liver and renal function tests. 
Creatinine kinase was occasionally elevated irrespective of treatment (n 
= 23; range 79–304 U/L; reference <149). Plasma ammonia levels 
remained (close to) normal throughout the observation period (n = 14; 
range 31–62 μmol/L; reference range 11–51 μmol/L). 
Plasma acylcarnitine profiles are reflective of the intracellular 
metabolization of triheptanoin (19). Analysis of plasma acylcarnitine 
profiles (n = 15; 3 measurements before and 12 under triheptanoin 
treatment) revealed slightly increased C3 acylcarnitine levels under 
triheptanoin treatment indicating cellular uptake and metabolism 
(Fig. 3). Free carnitine (C0) levels as well as the most abundant short 
chain acylcarnitines C2, C4 and C5 did not change significantly after 
Table 2 
Oxygraphic analysis of patient’s fibroblasts. Results of oxygraphic analysis were 
normal except for a decreased pyruvate/succinate respiration rate (bold).  




Pyruvate respiration (complex I 
dependent respiration) 
44.2 40–86 
Succinate respiration (complex II 
dependent respiration) 
62.9 35–70 
Max. respiration 85.9 62–110 
Max. uncoupled respiration 120.1 75–143 
Complex IV dependent respiration 129.5 67–162 
Pyruvate/succinate respiration rate 0.7 0.86–1.42  
Fig. 2. Video ratings during the first twelve months of trial. Her overall motor skills got better over time. For details, including improved items, see supplementary 
table 2. 
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introduction of triheptanoin, whereas C18 modestly decreased (Fig. 3). 
Total carnitine levels remained stable throughout the triheptanoin 
treatment period (data not shown). 
Analysis of urinary organic acid profiles (n = 28; 12 measurements 
before and 16 under triheptanoin treatment) revealed normal concen-
trations of malate, fumarate and succinate despite several metabolic 
decompensations before triheptanoin treatment (Fig. 4). Malate excre-
tion marginally increased upon triheptanoin treatment but remained in 
the normal range (Fig. 4). Except for pimelate, which slightly increased 
upon triheptanoin treatment as expected, the vast majority of the other 
63 analysed organic acids showed no (relevant) increase or change (data 
not shown). 
Analysis of plasma amino acid profiles (n = 14; 3 measurements 
before and 11 under triheptanoin treatment) revealed normal levels of 
serine and glycine throughout the observation period whereas gluta-
mine and threonine levels slightly increased upon triheptanoin treat-
ment (Fig. 5). None of the other 38 analysed amino acids showed any 
significant abnormalities or response to triheptanoin (data not shown). 
Strikingly, plasma lactate levels decreased significantly under tri-
heptanoin treatment while the ratio of lactate/pyruvate did not alter 
significantly (Fig. 6). 
4. Discussion 
MDH2D is an ultra-rare disease which has been described in only 
three patients to date (1). Metabolic decompensation occurred in 
context of infections and other catabolic situations. Our patient’s 
phenotype is in accordance with the above-mentioned patients (1). 
Clinical presentation of MDH2D is rather unspecific and resembles 
mitochondrial defects. Brain MRI revealed nonspecific findings 
including atrophy of the brain and delayed myelination (Fig. 1). A 
sensitive but unspecific biochemical marker for MDH2D is an elevated 
lactate in plasma and CSF. Interestingly all four patients described thus 
far (including our patient) share a common mutation on one allele of the 
MDH2 gene (c.398C>T, p.(Pro133Leu); see Supplementary Table 1) (1). 
Defects in the TCA cycle such as MDH2D limits the flux of pyruvate to 
complex I and consequently reduces complex I dependent respiration 
(20). In contrast succinate as a complex II substrate can be directly fed 
into complex II avoiding the TCA cycle (21). This is in line with the 
decreased pyruvate-/succinate-respiration-ratio detected in oxygraphic 
analysis in our patient’s cultured fibroblasts (Table 2). 
MDH2D causes an energy undersupply due to the different role of the 
enzyme. On one hand it leads to an interruption of the TCA cycle and 
mitochondrial NADH production. As part of the MAS, MDH2 is 
furthermore essential for the intracellular NADH/NAD+ homeostasis. 
The net effect of the MAS is the transfer of NADH generated in the 
cytosol into the mitochondria. By doing so the MAS restores the cyto-
solic NAD+ pool and simultaneously enables the intramitochondrial re- 
oxidation of NADH to NAD+. Mutations in MDH2 therefore also impair 
the transfer of cytosolic NADH into the mitochondria and they impair 
the cytosolic regeneration of NAD+ from NADH (1,2). One of the main 
biochemical consequences of MDH2D is an increased conversion of 
pyruvate into lactate by the lactate dehydrogenase which not only en-
ables (compensatory) re-oxidation of cytosolic NADH into NAD+ but 
also increases lactate levels (as observed in our and the three previously 
reported patients, Fig. 6) (1,2). 
A therapeutic strategy to attenuate the effects of MDH2D is to in-
crease the amount of available substrates in the mitochondria to ensure 
a proper flux of energy through the TCA cycle and to improve the 
intracellular NADH/NAD+ homeostasis by bypassing the MAS (Fig. 7). 
Fig. 3. Analysis of plasma acylcarnitine profiles (n = 15; 3 measurements before and 12 under triheptanoin treatment). Shown is a scatter dot plot and the median 
concentration of free carnitine (C0) and some of the most abundant acylcarnitines C2, C3, C4, C5 and C18. Plasma C3 acylcarnitine levels increased in response to 
triheptanoin treatment indicating cellular uptake and metabolism (p = 0.0566; Student’s t-test) and C18 decreased significantly (p = 0.0297). In contrast, none of the 
other acylcarnitines changed significantly. ULN, upper limit of normal; LLN, lower limit of normal. 
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Using MCTs as a treatment for MAS defects has been suggested (2). 
Therefore, a clinical trial with the odd-chain triglyceride trihepta-
noin known for its anaplerotic effect was introduced and well tolerated 
by our patient. The results of triheptanoin treatment were considered 
satisfactory. Video ratings showed an overall improvement in motor 
skills during the treatment period (Fig. 2 and Supplementary Table 2). 
After 12 months of therapy, parents reported an increased attention 
span, more constructive interactions with her environment as well as an 
improvement in her playing habits. On the other hand, clinical assess-
ment applying MACS and GMFCS revealed only modest improvements. 
These classification systems are not sensitive enough to capture subtle 
skill improvements (18). In addition, the hyperkinetic movement dis-
order resulting from a metabolic stroke, is probably irreversible irre-
spective of the applied treatment. 
While it is difficult to differentiate between the effects of trihepta-
noin treatment and the spontaneous remission the patient might have 
undergone during the observation period, it is impressive how her 
medical condition improved. Most strikingly during the entire treatment 
period she did not suffer from any metabolic decompensation unlike the 
6 metabolic decompensations she experienced prior to treatment with 
triheptanoin. From a biochemical point of view the most striking result 
was a significant decrease in plasma lactate levels in response to tri-
heptanoin (Fig. 6). A decrease in plasma lactate is most likely reflective 
of an improved cytoplasmic NADH/NAD+ ratio related to the therapy. 
Further studies are needed to evaluate the effect of triheptanoin in 
MDH2D. 
An additional and potentially beneficial effect of triheptanoin 
treatment is the utilization of heptanoate for gluconeogenesis (22). 
Further, glycerol as part of triheptanoin can also be used for pyruvate 
production (9). In the mitochondria pyruvate may be used for anaple-
rosis via the pyruvate carboxylase to yield oxaloacetate (20,23) entering 
Fig. 4. Analysis of urinary organic acid profiles (n = 28; 12 measurements before and 16 under triheptanoin treatment). Shown is a scatter dot plot and the median 
excretion of malate, fumarate and succinate. While malate excretion marginally increased upon triheptanoin treatment (p = 0.0116; Student’s t-test), fumarate and 
succinate remained unchanged. ULN, upper limit of normal. 
Fig. 5. Analysis of plasma amino acid profiles (n = 14; 3 measurements before 
and 11 under triheptanoin treatment). Shown is a scatter dot plot and the 
median concentration of serine, glycine, glutamine and threonine. While all 
serine and glycine values were in the reference range and no change was 
observed in response to triheptanoin treatment, glutamine and threonine levels 
increased slightly above the reference range. ULN, upper limit of normal; LLN, 
lower limit of normal. 
Fig. 6. Plasma lactate concentrations before and under treatment with tri-
heptanoin. Shown is a scatter dot plot and the median lactate levels which 
significantly decreased under treatment with triheptanoin (p = 0.001; Student’s 
t-test) while the ratio lactate/pyruvate did not change significantly. ULN, upper 
limit of normal; LLN, lower limit of normal. 
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the TCA cycle. Another anaplerotic effect of triheptanoin could be the 
increased amount of acetyl-CoA entering the TCA cycle thereby gener-
ating more intramitochondrial NADH. This explanation has been pre-
viously suggested by others and can be best illustrated when splitting the 
TCA cycle into two functionally complementary mini-cycles (1,17,24). 
Last but not least, the glycerol could be entering the glycerol-3- 
phosphate shuttle, another mechanism allowing re-oxidation of NAD+
from NADH in the cytosol (2). 
Taken together, triheptanoin has a therapeutic benefit on brain en-
ergy deficit caused by impaired TCA cycle and/or glucose metabolism 
(8,9). In MDH2D it directly supplies the TCA cycle with intermediates 
(acetyl-CoA, propionyl-CoA and glycerol). Further, triheptanoin 
partially bypasses the MAS defect by beta-oxidation of C7 and consec-
utive intramitochondrial generation of NADH (Fig. 5). Another mecha-
nism of action related to triheptanoin is the provision of an alternative 
source of energy in terms of ketone bodies. These help stabilizing the 
membrane potential in epileptic brains and modulate the balance be-
tween catabolic and anabolic pathways through anaplerosis of the TCA 
cycle in different diseases (7–9,11,19,25). 
Other MDH deficient patients have been treated with a ketogenic 
diet, which reduced the frequency of epileptic seizures. Two of the pa-
tients described in literature are still alive. One died due to a metabolic 
decompensation (2). Compared to ketogenic diet, triheptanoin is far less 
restrictive and very simple in its administration leading to a better 
compliance (7–11,25). 
5. Conclusion 
The MDH2 deficient patient described in this case study benefited 
from a drug trial with triheptanoin. A target dose of 55 mL was well 
tolerated by the patient. Weight and height development normalized 
under treatment, her social abilities and medical condition improved. 
Triheptanoin might be a therapeutic approach for MDH2D. More 
research is needed to clarify how triheptanoin interferes with the dis-
ease, to consolidate the present findings and to further support its 
therapeutic effectiveness. 
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